Abstract:
본발명은휘발성유기화합물류중의하나인톨루엔(Toluene)의인체노출정도에따라발현변화를일으키는특이적인유전자발현여부확인용바이오마커및 이를이용한확인방법에관한것으로, 보다구체적으로톨루엔의노출정도에따라특이적으로유전자발현이변화하는바이오마커및 이를이용한톨루엔에대한인체노출여부를확인하는방법에관한것이며, 본발명의바이오마커는 DNA 마이크로어레이칩을통하여선별된반응유전자들을바이오마커로이용하여환경중 노출된인체시료에서톨루엔의오염을모니터링및 판정하는데유용하게사용될수 있으며, 톨루엔에의해유발되는독성작용기작을규명하는도구로이용될수 있다.
Abstract:
PURPOSE: A method for detecting toxicity-inducing drug is provided to monitor and determine drugs or chemicals having toxicity. CONSTITUTION: A DNA microarray chip for detecting human toxicity-inducing drug contains: entire nucleic acid sequence of gene groups 1 to 6; an oligonucleotide which is a fragment having 18-30 nucleic acid sequences; or complementary stand thereof. A method for detecting human toxicity-inducing drug comprises: a step of treating a test compound to human cell line; a step of isolating RNA from an test compound-treated experimental group and a control group; a step of synthesizing the RNAs into cDNA and labeling with different fluorescence; a step of hybridizing with a DNA microarray; a step of analyzing the DNA microarray chip; and a step of comparing expression level between the control group and experimental group.
Abstract:
PURPOSE: A method for evaluating affect of thyroid hormone disruptive material to the activity of thyroid grand peroxidase is provided. CONSTITUTION: A transformed cell line(deposit number KCLRF-BP-00215) has a thyroid peroxidase gene which is transduced. A method for evaluating the affect of a thyroid hormone disruptive material to the activity of thyroid grand peroxidase comprises: a step of culturing the transformed cell line; a step of treating the thyroid hormone disruptive material to the transformed cell line; a step of measuring the thyroid peroxidase activity; and a step of comparing the activity with control group. The thyroid hormone disruptive material is an agricultural chemicals, organic heavy metals, dioxin, or synthetic estrogens.
Abstract:
본 발명은 폐독성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 더욱 상세하게는 폐독성 유발 약물인 카르바마제핀(carbamazepine)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 폐독성 유발 약물의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 폐독성의 위험성을 지닌 약물 또는 화학물질을 모니터링 및 판정하는데 유용하게 사용될 수 있으며, 카르바마제핀이 폐독성 및 부작용을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다. 카르바마제핀, 마커유전자, 마이크로어레이, 폐독성
Abstract:
본 발명은 심혈관독성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 더욱 상세하게는 심혈관독성 유발 약물인 다우노루비신(Daunorubicin)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 심혈관독성 유발 약물의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 심혈관독성의 위험성을 지닌 약물 또는 화학물질을 모니터링 및 판정하는데 유용하게 사용될 수 있으며, 다우노루비신이 심혈관독성 및 부작용을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다. 다우노루비신, 마커유전자, 마이크로어레이, 심혈관독성
Abstract:
PURPOSE: A biomarker for screening teratogenicity-inducing chemical is provided to increase or decrease gene expression by methotrexate treatment and monitor chemical. CONSTITUTION: A gene expression of biomarker for screening teratogenicity-inducing chemical is increased or decreased by treating with a drug. The drug is methotrexate. A DNA microarray chip for screening the chemical comprises oligonucleotide containing whole or partial biomarker gene or its complementary oligonucleotide. A method for screening the chemical comprises: a step of treating test compound to human placenta-derived cells; a step of isolating RNA from the compound-treated experimental group and control group; a step of synthesizing cDNA and labeling the experimental group and control group with different color fluorescence; a step of hybridizing cDNA with DNA microarray chip; a step of analyzing DNA microarray chip; and a step of comparing experimental group with the control group.
Abstract:
A biomarker for identifying the exposure to malachite green is provided to specifically increase or decrease the expression by the malachite green and monitor the pollution by the malachite green. A biomarker for identifying the exposure to a malachite green comprises: a gene registration number (GeneBank) AB000584(Growth differentiation factor 15); a gene registration number NM_030581(Homo sapiens WD repeat domain 59)(WDR59); a gene registration number AK026623(Homo sapiens nuclear-encoded mitochondrial cytochrome C oxidase Va subunit); and a gene registration number DQ282439(Homo sapiens isolate B2-1-06 mitochondrion(cytochrome C oxidase subunit1). A method for identifying the exposure to the malachite green comprises: a step of isolating RNA from a human somatic cells and control somatic cells; a step of synthesizing RNA to cDNA (complementary DNA); a step of hybridizing the cDNA with DNA microarray chip; a step of analyzing DNA microarray chip; and comparing the expression level between control group and sample group.
Abstract:
본 발명은 최기형성 유발 약물 검색용 마커유전자 및 이를 이용한 검색 방법에 관한 것으로, 구체적으로 최기형성 유발 약물인 탈리도마이드 (Thalidomide)에 의해 유전자 발현이 증가 또는 감소하는 마커유전자 및 이를 이용한 탈리도마이드의 검색 방법에 관한 것이다. 본 발명의 마커유전자는 DNA 마이크로어레이 칩을 통하여 선별된 반응 유전자들을 마커유전자로 이용하여 새로운 최기형성 위험성을 지닌 약물 또는 화학물질 모니터링 및 위해성을 판정하는데 유용하며, 최기형성을 일으키는 작용 기작을 규명하는 도구로 이용될 수 있다. 탈리도마이드, 마커유전자, 마이크로어레이, 최기형성
Abstract:
A marker gene, a DNA microarray chip for screening the teratogenecity inducing drugs, and a method for screening the teratogenecity inducing drugs by using the chip are provided to the drugs inducing teratogenecity to be screened effectively. A marker gene is used to screen the teratogenecity inducing drugs and comprises the gene selected from Genebank NM_032199 [AT rich interactive domain 5B (MRF1-like)], Genebank BX647857 [Ankyrin repeat and SOCS box-containing 5], Genebank NM_013314 [B-cell linker], Genebank AB018258 [ATPase, Class V, type 10B], Genebank BX111592 [Transcribed locus], etc.
Abstract:
A biomarker is provided to be usefully used in order to monitor and determine a volatile organic compound which is harmful to environment or real life using reaction genes selected through a DNA microarray chip and be used as a tool for investigating mechanism how the volatile organic compound causes toxicity. A biomarker for screening a volatile organic compound includes a gene selected from the group consisting of Genebank BC071718[Chemokine(C-C motif) ligand 4-like 1], Genebank NM_022168(Interferon induced with helicase C domain 1), Genebank AK095515(Interferon-induced protein with tetratricopeptide repeats 1), Genebank CD521853[Chemokine(C-C motif) ligand 4], Genebank AK023956(2'-5'-oligoadenylate synthetase-like), Genebank BC032839(Interferon-induced protein with tetratricopeptide repeats 2), Genebank AF026939(Interferon-induced protein with tetratricopeptide repeats 3), Genebank BX649185[B-cell CLL/lymphoma 6(zinc finger protein 51)], Genebank AI742278(Interleukin 8), Genebank X74328[Cannabinoid receptor 2(macrophage)], Genebank BF690887(BCL2-related protein A1), Genebank NM_001165(Baculoviral IAP repeat-containing 3), Genebank D90070(Phorbol-12-myristate-13-acetate-induced protein 1), Genebank M83221(V-rel reticuloendotheliosis viral oncogene homolog B), Genebank NM_004430(Early growth response 3), Genebank AK123009(Growth factor independent 1), Genebank NM_003764(Syntaxin 11), Genebank NM_014331(Solute carrier family 7, member 11), Genebank NM_000104(Cytochrome P450, family 1, subfamily B, polypeptide 1), Genebank AY123223(Sestrin 2), Genebank NM_002395[Malic enzyme 1, NADP(+)-dependent, cytosolic], Genebank NM_024625(Zinc finger CCCH-type, antiviral 1), Genebank AF302505[Pellino homolog 1(Drosophila)], Genebank AL834442(Nuclear receptor coactivator 7), Genebank NM_017414(Ubiquitin specific peptidase 18), Genebank NM_002133[Heme oxygenase (decycling) 1], Genebank AY337518(Hect domain and RLD 5), Genebank D80008(DNA replication complex GINS protein PSF1). A DNA microarray chip for searching the volatile organic compound is characterized in that an oligonucleotide or a complementary strand molecule including a total or a portion of the biomarker gene sequence is integrated. A method for screening the volatile organic compound comprises the steps of: (a) treating a human myelogenous leukemia cell with a compound to be tested; (b) isolating RNA respectively from the test group treated with the compound to be tested and a control group not treated with the compound to be tested; (c) labelling the test group and the control group respectively with a fluorescent material different from each other with synthesizing the RNA into cDNA; (d) hybridizing the cDNA labelled with the fluorescent material into the DNA microarray chip; (e) analyzing the reacted DNA microarray chip; and (f) comparing the expression degree of the biomarker with the data analyzed from the step(e). A kit for screening the volatile organic compound includes the DNA microarray chip.